OakChart

Bionano Genomics Inc

BNGOHealthcare·Medical Instruments & Supplies·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.10-0.13 (-10.57%)
2026-11-12 05:38 CET
Market cap
15.38 USD m
Revenue, TTM
31.09 USD m
Net income, TTM
-30.11 USD m
Free cash flow, TTM
-19.09 USD m
EPS diluted, TTM
-2.68
P/E
-
Compare

Price

BNGO against its 20, 50 and 200-day averages
2050200beatmiss
1.001.502.0019.9M39.8MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BNGOclose 1.1020-day 1.1950-day 1.37200-day 1.231.1052w high52w low

50.7% under the 52-week high of 2.23 on 15 Sep 2026. 52-week low 1.00 on 31 Jul 2026. Last 15 sessions, 26.2% high to low

Volume 0.62× normal · the line is the 50-bar volume average

Profile

BNGO
52-week range, 8% of the way up
1.002.23

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Employees97
IPOSep 21, 2018
Beta1.68
ATR, 14d0.10
Rel volume0.62
Short float10.55%
Insider own5.93%
Inst own17.84%

Snapshot

6 groups

Valuation

Index-
Market Cap15.37M
Enterprise Value13.24M
Income-30.11M
Sales31.09M
Book/sh2.09
Cash/sh0.62
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees97
IPOSep 21, 2018

Ratios

P/E-
Forward P/E-
PEG-
P/S0.49
P/B0.53
P/C1.77
P/FCF-
EV/EBITDA-
EV/Sales0.43
Quick Ratio1.54
Current Ratio2.07
Debt/Eq0.23
LT Debt/Eq0.20
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.68
EPS next Y-0.97
EPS next Q-0.39
EPS this Y67.10%
EPS next Y54.67%
EPS next 5Y56.92%
EPS past 3/5Y73.98% 54.05%
Sales past 3/5Y0.84% 27.37%
EPS Y/Y TTM82.76%
Sales Y/Y TTM8.23%
EPS Q/Q66.21%
Sales Q/Q12.34%
EarningsNov 10 AMC
EPS/Sales Surpr.0.00% -1.98%

Ownership

Insider Own5.93%
Insider Trans0.97%
Inst Own17.84%
Inst Trans-1.09%
ROA-48.04%
ROE-77.20%
ROIC-88.85%
Gross Margin47.98%
Oper. Margin-97.11%
Profit Margin-96.87%
SMA20-7.83%
SMA50-19.47%
SMA200-10.33%
Trades-

Technical

Shs Outstand13.51M
Shs Float13.15M
Short Float10.55%
Short Ratio1.47
Short Interest1.39M
52W High2.23 -50.67%
52W Low1.00 10.00%
Volatility11.58% 7.05%
ATR (14)0.10
RSI (14)38.37
Beta1.68
Rel Volume0.62
Avg Volume940.96K
Volume583,878

Performance

Perf Week-7.56%
Perf Month-19.12%
Perf Quarter-6.78%
Perf Half Y-12.00%
Perf YTD-28.10%
Perf Year-32.10%
Perf 3Y-98.59%
Perf 5Y-99.96%
Perf 10Y-
Recom1.00
Target Price4.00
Prev Close1.23
Price1.10
Change %-10.57%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Nov 15, 2024DowngradeLLadenburg ThalmannBuy → Neutral
Sep 10, 2024DowngradeBBTIG ResearchBuy → Neutral
Jan 05, 2023InitiatedBScotiabankSector Outperform$4+263.6%
Dec 12, 2022ResumedBBTIG ResearchBuy$3.50+218.2%
Jul 18, 2022ResumedOOppenheimerOutperform$12+990.9%
Jun 16, 2021InitiatedBBTIG ResearchBuy$10+809.1%
Sep 24, 2020InitiatedLLadenburg ThalmannBuy$1.25+13.6%
Apr 08, 2020InitiatedOOppenheimerOutperform$1.50+36.4%

Peers

Mkt cap
TickerCompanyMkt cap
PACBPacific Biosciences of California Inc654.02M
TXG10x Genomics Inc8.08B
HBIOHarvard Bioscience Inc44.06M
ILMNIllumina Inc32.20B
LABStandard BioTools Inc253.85M
AAgilent Technologies Inc49.89B
QSIQuantum-Si Incorporated279.07M
QTRXQuanterix Corp143.39M
SEERSeer Inc88.04M
NAUTNautilus Biotechnology Inc308.24M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Luderer AlbertInterim Chief ExecutiveSep 04 '26Buy1.214,0004,8458,000Sep 09 04:30 PM
Luderer AlbertInterim Chief ExecutiveAug 21 '26Buy1.224,0004,8604,000Aug 21 04:30 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Bionano Misses As Growth Slows And Cash Thins, Leaving A Reimbursement-Driven 2027 Story To Carry The Weight (Earnings Whispers) +6.03% -10.57%
  • Bionano Reports Third Quarter 2026 Results and Provides a Business Update (GlobeNewswire)
  • Bionano's Q3 Test: Can Flow Cell Supply And Thin Cash Keep Pace With Demand? (Earnings Whispers)
  • Bionano to Report Third Quarter 2026 Financial Results and Host a Conference Call Webcast on November 10, 2026 (GlobeNewswire) +5.17%
  • Bionano Announces Three New Peer-Reviewed Studies Demonstrate Clinical Value of Bionano's Optical Genome Mapping Across Myelodysplastic Syndromes and Acute Myeloid Leukemia (GlobeNewswire) +9.02%
  • Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ... (GuruFocus.com)
  • Bionano Reports Second Quarter 2026 Results and Provides a Business Update (GlobeNewswire)
  • Earnings To Watch: Bionano Genomics Inc (BNGO) Q2 2026 -- GF Value Sees 27% Upside (GuruFocus.com) +5.45%
  • Bionano to Report Second Quarter 2026 Financial Results and Host a Conference Call Webcast on August 10, 2026 (GlobeNewswire)
  • Bionano Announces Hiring of Chief Scientific Officer (GlobeNewswire)
  • Bionano Announces 67% Year-Over-Year Growth in Studies Featuring Optical Genome Mapping at ESHG 2026, Reflecting Expanding Global Adoption (GlobeNewswire)
  • Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders (GlobeNewswire)
  • Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.450-0.450-0.5388.288.441
2026Q22026-08-10-0.660-0.670-0.6438.177.551
2026Q12026-05-13-0.760-0.880-0.7566.696.572
2025Q42026-03-23-1.550-2.475-0.7397.957.882
2025Q32025-11-13-2.040-2.075-1.5937.376.912
2025Q22025-08-14-2.000-2.657-1.9936.736.562
2025Q12025-05-14-1.151-3.023-1.1516.466.253
2024Q42025-03-31-13.327-5.898-10.7898.166.002
2024Q32024-11-13-31.200-11.851-30.9166.077.764
2024Q22024-08-07-15.450-24.918-14.4047.808.023
2024Q12024-05-08-35.916-38.646-35.7488.778.484
2023Q42024-03-05-68.700-52.242-57.55910.7010.554
2023Q32023-11-08-193.16-58.182-192.979.329.085
2023Q22023-08-09-71.640-62.550-74.1248.668.295
2023Q12023-05-09-70.002-66.000-73.7467.427.364
2022Q42023-03-10-74.400-67.446-78.0908.228.105

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-914-1,218-1,19410.1311.76
2020FY-117.66-240-236.588.508.00
2021FY-156-148.88-157.0217.9817.26
2022FY-264.19-256.52-275.0927.8027.69
2023FY-412.34-396.73-408.4836.1035.97
2024FY-88.090-80.100-88.13530.7828.80
2025FY-6.505-6.395-8.16028.5128.44
2026FY--2.140--32.47
2027FY--0.970--43.30
2028FY--0.520--54.80
2029FY--0.240--66.51
2030FY-0.200--80.69

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-111009.179.179.17
2026Q4S2026-11-101009.179.179.17
2026Q4S2026-10-251009.179.179.17
2026Q4S2026-08-111019.179.179.17
2026Q4S2026-07-191009.499.499.49
2026Q4S2026-06-242009.499.499.50
2026Q4S2026-06-102019.499.499.50
2026Q4S2026-05-282029.499.499.50
2026Q4S2026-05-142029.479.459.50
2026Q4S2026-04-102029.479.459.50
2026Q4S2026-03-302019.629.459.80
2026Q4S2026-03-272019.629.459.80
2026Q4S2026-03-242019.999.8010.17
2026Q4S2026-03-042019.999.8010.17

Estimate history

EPS, annual-1402.56-1568.13-1194.36-236.58-157.02-275.088-408.479-88.135-4.848-2.676
Period201720182019202020212022202320242025TTM
EPS, quarterly-30.916-10.789-1.151-1.993-1.593-0.739-0.756-0.643-0.538
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual9.50512.00110.138.50317.98127.80236.11630.77628.50831.09
Period201720182019202020212022202320242025TTM
Sales, quarterly6.0738.1636.4576.7337.3677.9516.6878.1718.276
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0170.0170.0570.3170.4830.4950.7631.86510.7413.509
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.4741.8653.1013.9099.7310.7411.27711.77713.509
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue31.0928.5130.7836.1227.8017.988.5010.1312.00
Cost of Goods Sold Incl. D&A16.1722.2541.4626.5530.4617.186.667.858.71
Gross Profit14.916.26-10.699.57-2.650.801.842.273.29
Selling, General and Administrative Excl. Other45.1039.6075.03148.99126.9377.9038.8928.1523.70
Research and Development12.4011.3724.8054.0349.0522.4810.269.089.48
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-30.19-33.34-85.71-139.43-129.58-77.10-37.05-25.87-20.42
Interest Expense0.280.300.295.120.300.932.522.291.38
Unusual Expense1.19-3.7826.0794.642.120.301.501.33-3.99
Net Income Before Taxes-30.05-26.33-111.98-232.43-130.71-78.15-41.08-29.79-18.48
Income Taxes0.060.070.030.061.88-5.720.030.020.02
Consolidated Net Income-30.11-26.39-112.02-232.49-132.60-72.44-41.11-29.82-18.50
Net Income From Continuing Operations-30.11-26.39-112.02-232.49-132.60-72.44-41.11-29.82-18.50
Net Income-30.11-26.39-112.02-232.49-132.60-72.44-41.11-29.82-18.50
EPS (Recurring)-2.44-5.33-73.78-292.08-272.01-156.57-230.54-1,156.97-1,804.98
EPS (Basic, Before Extraordinaries)-2.68-4.85-88.13-408.48-275.09-157.02-236.58-1,194.36-1,568.13
EPS (Diluted)-2.68-4.85-88.13-408.48-275.09-157.02-236.58-1,194.36-1,568.13
EBITDA-20.75-23.61-71.48-125.72-119.48-73.13-35.58-24.75-19.09
Non-Operating Income (Expense)1.603.520.096.761.280.18-0.01-0.30-0.68
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.263.587.6911.9917.717.091.130.980.94
Price To Sales Ratio-0.290.711.7915.1946.0337.761.833.09
Gross Margin47.9821.95-34.7226.49-9.554.4721.6722.4627.41
Operating Margin-97.11-116.95-278.50-386.05-466.09-428.79-435.74-255.44-170.12
Net Margin-96.87-92.59-363.98-643.74-476.93-402.84-483.43-294.34-154.13
Shares Outstanding13.5110.741.870.760.500.480.320.060.02
Market Capitalization15.3815.3832.2866.81433.47865.91585.0642.5052.69

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue8.288.176.697.957.376.736.468.16
Cost of Goods Sold Incl. D&A4.333.863.444.554.003.263.524.75
Gross Profit3.954.313.253.403.373.482.943.42
Selling, General and Administrative Excl. Other10.4811.5311.1511.9411.9111.2811.4013.92
Research and Development3.042.993.143.232.842.932.373.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.54-7.22-7.90-8.54-8.54-7.80-8.46-10.50
Interest Expense0.070.070.070.070.070.070.090.03
Unusual Expense0.000.290.460.440.260.59-5.078.38
Net Income Before Taxes-6.45-7.42-8.29-7.90-8.49-6.85-3.10-20.12
Income Taxes0.010.010.010.040.010.010.010.00
Consolidated Net Income-6.45-7.42-8.30-7.93-8.50-6.86-3.10-20.12
Net Income From Continuing Operations-6.45-7.42-8.30-7.93-8.50-6.86-3.10-20.12
Net Income-6.45-7.42-8.30-7.93-8.50-6.86-3.10-20.12
EPS (Recurring)-0.54-0.63-0.73-0.71-1.56-1.87-2.47-7.64
EPS (Basic, Before Extraordinaries)-0.54-0.64-0.76-0.74-1.59-1.99-1.15-10.79
EPS (Diluted)-0.54-0.64-0.76-0.74-1.59-1.99-1.15-10.79
EBITDA-4.20-4.87-5.54-6.15-6.11-5.47-5.98-8.05
Non-Operating Income (Expense)0.160.160.131.150.381.610.38-1.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.240.770.530.730.740.851.251.53
Price To Sales Ratio-0.430.450.580.320.410.261.05
Gross Margin47.7252.8048.6342.7545.7451.6445.5041.86
Operating Margin-78.98-88.34-118.09-107.36-115.90-115.85-131.10-128.67
Net Margin-77.97-90.85-124.17-99.77-115.42-101.84-48.04-246.54
Shares Outstanding13.5111.7811.2810.749.733.913.101.87
Market Capitalization15.3812.9712.9815.5716.6811.037.6232.28

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments29.5420.48101.89113.19250.6138.4517.3116.521.02
Short Term Receivables5.214.779.667.505.322.786.334.513.35
Inventories7.7211.1822.8930.0112.674.463.851.142.19
Other Current Assets2.923.065.686.613.811.100.760.840.58
Total Current Assets45.3939.49140.12157.30272.4146.7928.2623.037.14
Net Property, Plant & Equipment21.1624.3232.4828.9620.934.911.951.783.01
Total Investments and Advances0.000.400.400.400.000.000.000.000.00
Intangible Assets4.349.7133.97118.3383.008.650.000.000.00
Other Assets2.692.757.432.520.750.100.000.000.00
Total Assets73.5876.67214.40307.50377.1060.4530.2124.8010.15
Short Term Debt Incl. Current Port. of LT Debt10.9323.6180.772.541.770.0020.080.006.73
Accounts Payable5.596.9610.3812.539.702.932.701.352.30
Income Tax Payable0.27--------
Other Current Liabilities6.166.778.8720.8010.386.013.583.177.62
Total Current Liabilities22.9437.34100.0335.8821.848.9426.374.5216.65
Long Term Debt5.973.687.179.128.9316.330.009.030.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.250.2711.0413.109.210.100.231.110.71
Total Liabilities29.1641.30118.2558.1039.9825.3726.5914.6717.36
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.0043.01
Common Equity44.4235.3896.16249.40337.1235.083.6110.14-50.23
Total Shareholders Equity44.4235.3896.16249.40337.1235.083.6110.14-7.22
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity44.4235.3896.16249.40337.1235.083.6110.14-7.22
Total Liabilities & Stockholders Equity73.5876.67214.40307.50377.1060.4530.2124.8010.15
Book Value Per Share4.1418.96126.10503.52698.44110.8163.26604.91-3,015.01
Tangible Book Value Per Share3.7313.7681.55264.62526.4883.5063.26604.91-3,015.01
Full-Time Employees971003444052991479777-
Price to Book Ratio0.530.910.561.542.5716.6811.765.203.23
Return on Assets-35.13-76.97-89.09-38.74-33.11-90.69-108.40-105.85-187.43
Return on Equity-66.15-170.33-134.56-45.21-38.92-212.46-433.64-1,266.76-
Return on Invested Capital-52.38-286.79-225.00-51.29-20.93-79.96-825.05-96.50-
Quick Ratio1.640.761.173.5511.894.730.934.840.30
Current Ratio1.981.061.404.3812.475.231.075.090.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-30.11-26.39-112.02-232.49-132.60-72.44-41.11-29.82-18.50
Depreciation9.449.7314.2313.7110.104.021.481.131.32
Other Funds (Non Cash)3.40-0.2022.72103.8524.519.914.754.13-0.40
Funds from Operations-17.27-16.86-75.07-114.93-96.23-64.28-34.87-24.56-17.57
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.810.514.40-14.77-28.59-7.65-3.44-4.97-2.37
Cash from Operating Activities-19.09-16.34-70.67-129.70-124.82-71.93-38.31-29.53-19.94
Capital Expenditures0.000.00-0.10-1.69-3.30-1.460.00-0.06-0.33
Net Assets From Acquisitions0.000.000.000.00-31.34-49.09-2.450.00-
Sale of Fixed Assets and Businesses0.000.000.000.100.720.000.000.00-
Purchase or Sale of Investments25.56-12.7573.9425.75116.69-226.910.000.000.00
Purchase of Investments-154.56-241.88-233.02-111.26-84.19-313.390.000.000.00
Sale Or Maturity of Investments180.12229.13306.96137.02200.8986.480.000.000.00
Other Uses0.000.000.000.000.00-0.610.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities25.56-12.7573.8424.1682.77-278.06-2.45-0.06-0.33
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.6528.9841.4956.3823.04351.1266.6320.5619.39
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.6528.9841.4956.3823.04351.1266.6320.5619.39
Proceedsfrom Stock Options5.6528.9841.4956.3622.70341.1037.9719.7019.39
Issuance or Reduction of Debt, Net-10.35-4.95-53.43-9.05-0.04-15.01-4.729.8216.38
Change in Long Term Debt-0.08-0.07-0.06-0.05-0.04-15.01-3.239.8216.38
Issuance of Long Term Debt0.000.000.000.000.000.001.7724.2523.83
Reduction of Long Term Debt-0.08-0.07-0.06-0.05-0.04-15.01-5.00-14.43-7.45
Net Financing Active Other Cash Flow0.000.000.0071.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.00-9.000.000.000.000.000.00
Cash from Financing Activities-4.7024.04-11.94118.3423.01336.1161.9030.3835.78
Exchange Rate Effect0.01-0.01-0.010.07-0.04----
Net Change in Cash1.79-5.06-8.7812.86-19.08-13.8821.140.7915.50
Free Cash Flow-19.09-16.34-70.77-131.39-128.02-73.39-38.31-29.59-20.28
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.001.76-5.780.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments8.6710.4224.6729.5431.8527.44
Short Term Receivables5.854.374.135.214.533.49
Inventories6.515.205.317.727.058.63
Other Current Assets4.484.894.862.925.383.10
Total Current Assets25.5224.8838.9845.3948.8042.66
Net Property, Plant & Equipment17.9818.9520.1521.1622.8224.23
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.331.673.004.345.687.03
Other Assets2.472.102.682.691.762.09
Total Assets46.2947.5964.8073.5879.0676.01
Short Term Debt Incl. Current Port. of LT Debt0.860.8811.0410.9311.1013.36
Accounts Payable5.544.565.065.595.996.24
Income Tax Payable--0.200.27--
Other Current Liabilities5.914.604.926.165.894.57
Total Current Liabilities12.3110.0421.2322.9422.9824.18
Long Term Debt5.685.835.975.976.096.21
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.090.120.140.250.190.24
Total Liabilities18.0815.9827.3429.1629.2630.64
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity28.2131.6137.4644.4249.8045.37
Total Shareholders Equity28.2131.6137.4644.4249.8045.37
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity28.2131.6137.4644.4249.8045.37
Total Liabilities & Stockholders Equity46.2947.5964.8073.5879.0676.01
Book Value Per Share2.092.683.324.145.1211.61
Tangible Book Value Per Share2.062.543.063.734.539.81
Full-Time Employees---97--
Price to Book Ratio0.530.340.280.300.150.21
Return on Assets-48.04-52.04-44.12-35.13-46.37-72.39
Return on Equity-77.20-83.56-73.78-66.15-78.22-118.26
Return on Invested Capital-19.04-19.83-19.12-15.74-15.21-13.29
Quick Ratio1.541.961.591.641.821.41
Current Ratio2.072.481.841.982.121.76

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-6.45-7.42-8.30-7.93-8.50-6.86
Depreciation2.342.352.362.392.432.43
Other Funds (Non Cash)0.381.060.851.111.171.70
Funds from Operations-3.73-4.01-5.09-4.44-4.91-2.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.79-0.66-0.630.26-1.01-0.76
Cash from Operating Activities-4.52-4.67-5.72-4.17-5.92-3.49
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments2.4113.685.464.01-4.671.98
Purchase of Investments-10.08-31.46-48.67-64.35-60.88-51.88
Sale Or Maturity of Investments12.4945.1454.1368.3656.2253.85
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities2.4113.685.464.01-4.671.98
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.760.590.681.6211.972.99
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.760.590.681.6211.972.99
Proceedsfrom Stock Options2.760.590.681.6211.972.99
Issuance or Reduction of Debt, Net-0.02-10.29-0.02-0.02-1.89-1.52
Change in Long Term Debt-0.02-0.02-0.02-0.02-0.02-0.02
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.02-0.02-0.02-0.02-0.02-0.02
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.74-9.690.661.6010.081.47
Exchange Rate Effect0.000.000.010.010.01-0.02
Net Change in Cash0.62-0.680.401.44-0.50-0.06
Free Cash Flow-4.52-4.67-5.72-4.17-5.92-3.49

Revenue breakdown

Consumable2024: 12.77M 2025: 13.97M
Instrument2024: 8.04M 2025: 6.36M
Product and Service, Other2024: 3.77M 2025: 1.77M
Software2024: 6.19M 2025: 6.41M
Americas2024: 13.65M 2025: 12.18M
Asia Pacific2024: 2.89M 2025: 2.22M
EMEA2024: 14.23M 2025: 14.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.55%1.4M13.2M935.01K
2026-10-1512.27%1.4M11.1M917.55K
2026-09-3018.37%2.0M11.1M910.18K
2026-09-1510.33%1.1M11.1M771.01K
2026-08-3111.04%1.2M11.1M135.73K
2026-08-1410.42%1.2M11.1M135.96K
2026-07-319.89%1.1M10.8M144.81K
2026-07-1510.08%1.1M10.8M148.50K
2026-06-3010.74%1.2M10.8M147.93K
2026-06-1510.46%1.1M10.8M310.80K
2026-05-2910.44%1.1M10.8M305.68K
2026-05-1511.38%1.2M10.8M296.76K
2026-04-3010.83%1.1M10.4M307.50K
2026-04-1511.12%1.1M10.3M348.45K
2026-03-3111.99%1.2M10.3M358.04K
2026-03-1311.53%1.1M9.5M190.64K
2026-02-2712.34%1.2M9.5M207.83K
2026-02-1312.64%1.2M9.5M240.90K
2026-01-3011.99%1.1M9.5M250.57K
2026-01-1511.12%1.1M9.5M250.45K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-05EFFECTEffectiveness filing by commission orderSEC
2026-11-05EFFECTEffectiveness filing by commission orderSEC
2026-11-02S-3/ASEC
2026-10-27S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-10-19SCHEDULE 13GSEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-08-054Statement of changes in beneficial ownership of securities2026-08-03SEC
2026-08-053Initial statement of beneficial ownership of securities2026-08-03SEC
2026-07-303Initial statement of beneficial ownership of securities2026-07-20SEC
2026-06-248-KCurrent report2026-06-24SEC
2026-06-058-KCurrent report2026-06-02SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-034Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-05-288-KCurrent report2026-05-28SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-14SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-094.84K100
2026-084.86K100
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
AIGH Capital Management LLC9.89%
GSA CAPITAL PARTNERS LLP1.31%
CARRET ASSET MANAGEMENT, LLC1.15%
ACADIAN ASSET MANAGEMENT LLC0.76%
VANGUARD CAPITAL MANAGEMENT LLC0.72%
GEODE CAPITAL MANAGEMENT, LLC0.66%
VANGUARD FIDUCIARY TRUST CO0.45%
RENAISSANCE TECHNOLOGIES LLC0.45%
JANE STREET GROUP, LLC0.31%
PRUDENTIAL FINANCIAL INC0.28%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.72%
Fidelity Extended Market Index Fund0.48%
Fidelity Series Total Market Index Fund0.10%
Fidelity Total Market Index Fund0.02%

OakChart. BNGO. Cached 15 minutes.